ChromaDex Q3 net sales $17.1M, net loss narrows to $1.0M; approaches cash flow breakeven

Niagen Bioscience, Inc.

2022-Q3 EPS reported -$0.22 revenue$51,054,000

Net loss of $1.0M ($0.01 loss per share) vs $8.8M loss in Q3 2021; Adjusted EBITDA loss narrowed to $1.2M.
Gross margin 59.8% (down from 61.1% YoY); operating expenses cut $6.1M to $13.3M, driven by lower legal and marketing costs.
Signed long-term supply agreement with Nestlé Health Science with ~$2.0M initial purchase commitment; raised $7.7M from Nestlé and strategic investors.
JV signed to pursue Blue Hat approval for Tru Niagen in Mainland China; clinical study in JACC found Niagen safe in heart failure patients.
Tru Niagen e-commerce sales steady but B2B sales declined due to COVID-19 headwinds and macro factors.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Niagen Bioscience, Inc. reported the quarter ended September 30, 2022 results: revenue $17.1 million, net income $1.0 million or $(0.01) per share, EPS $(0.01) per share.

Period: the quarter ended September 30, 2022
Revenue: $17.1 million
Net income: $1.0 million or $(0.01) per share
EPS: $(0.01) per share
Result: reported results

Exact text from the filing

ChromaDex Corporation Reports Third Quarter 2022 Financial Results Total net sales of $17.1 million

View on SEC.gov

Browse all earnings releases →

Niagen Bioscience, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-22-027801

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.